Momelotinib Yields Substantial Symptom Benefits Among Patients With Myelofibrosis

Phase 3 MOMENTUM Trial: Patient-Reported Outcomes 

Patient-reported outcomes from the phase 3 MOMENTUM trial demonstrated that momelotinib provided rapid and durable response benefits among anemic and symptomatic patients with myelofibrosis (MF).

Myelofibrosis “typically manifests with debilitating symptoms that progressively worsen, negatively impacting patients' quality of life. Fatigue is a multifactorial and burdensome MF-related symptom due to its severity, persistence, and prevalence, with anemia a contributing factor and major unmet need,” wrote Ruben A Mesa, MD, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, and coauthors.

Previous clinical trials utilizing the JAK1/JAK2/activin A receptor type 1 inhibitor momelotinib have shown consistent anemia benefits, in addition to improvements in symptoms related to MF. The MOMENTUM trial sought to investigate this further, and met its primary end point for symptomatic and anemic patients, with a greater proportion having a Myelofibrosis Symptom Assessment Form (MFSAF) Total Symptom Score (TSS) reduction ≥50% at week 24 with momelotinib versus danazol. 

To support the positive primary end point result, investigators conducted longitudinal, responder, and time-to-event analyses of patient-reported outcomes from MOMENTUM. These analyses were measured by the MFSAF, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), and Patient-Reported Outcomes Measurement Information System (PROMIS) assessments. 

Researchers concluded the use of momelotinib improved the quality of life and overall symptoms, specifically anemia, experienced among patients with MF, including achievement of first TSS response by day 29, with continued additional improvement over time. 

Overall, improvements favored momelotinib versus danazol for each MFSAF individual item, and greater improvements were noted for disease- and cancer-related fatigue and physical functioning at week 24, with significant results for multiple items/domains across the 3 assessments. 

Mesa and colleagues concluded that, “These findings are consistent in demonstrating that momelotinib provides substantial symptom benefit.”

Source:

Mesa R, Harrison C, Palmer J, et al. Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study. Hemasphere. 2023;7(11):e966. Published 2023 Oct 24. doi:10.1097/HS9.0000000000000966